A novel intravitreal fluocinolone acetonide implant (Iluvien®) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: A case series

Clinical Ophthalmology

Volumn 9, Issue , 2015, Pages 801-811

  Schmit Eilenberger, Vera K ^a  

^a STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

Author keywords

Best corrected visual acuity; Corticosteroid; Diabetic macular edema; Fluocinolone acetonide; Intravitreal implant

Indexed keywords

BEVACIZUMAB; BRINZOLAMIDE PLUS TIMOLOL; DEXAMETHASONE; DORZOLAMIDE PLUS TIMOLOL; FLUOCINOLONE ACETONIDE; RANIBIZUMAB; TRIAMCINOLONE;

ADULT; AGED; ARTICLE; CASE STUDY; CENTRAL FOVEA THICKNESS; CLINICAL ARTICLE; CRYOTHERAPY; DIABETIC MACULAR EDEMA; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTRAOCULAR PRESSURE; INTRAVITREAL IMPLANT; MALE; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PSEUDOPHAKIA; RETINAL THICKNESS; RETROSPECTIVE STUDY; SIDE EFFECT; VERY ELDERLY; VISUAL ACUITY; VITRECTOMY;

EID: 84982683332     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S79785     Document Type: Article

References (30)

1. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy: XV. The long-term incidence of macular edema. Ophthalmology. 1995;102(1):7–16.
2. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556–564.
3. Ferris FL, III, Patz A. Macular edema. A complication of diabetic retinopathy. Surv Ophthalmol. 1984;28(Suppl):452–461.
4. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol. 2009;54:1–32.
5. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology. 1998;105:998–1003.
6. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin epidemiologic study of diabetic retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology. 1998;105:1801–1815.
7. Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology. 1995;102:647–661.
8. Massin P, Audren F, Haouchine B, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology. 2004;111(2):218–224; discussion 224–225.
9. Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res. 2011;30(5):343–358.
10. Jonas JB, Kamppeter BA, Harder B, Vossmerbaeumer U, Sauder G, Spandau UH. Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study. J Ocul Pharmacol Ther. 2006;22(3):200–207.
11. Jonas JB. Intravitreal triamcinolone acetonide: a change in a paradigm. Ophthalmic Res. 2006;38(4):218–245.
12. Folkman J. Angiogenesis and apoptosis. Semin Cancer Biol. 2003;13(2):159–167.
13. Nakano T, Ohara O, Teraoka H, Arita H. Glucocorticoids suppress group II phospholipase A2 production by blocking mRNA synthesis and post-transcriptional expression. J Biol Chem. 1990;265(21):12745–12748.
14. Leopold IH. Nonsteroidal and steroidal anti-inflammatory agents. In: Sears M, Tarkkanen A, editors. Surgical Pharmacology of the Eye. New York, NY: Raven Press; 1985:83–133.
15. Edelman JL, Lutz D, Castro MR. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood aqueous barrier breakdown. Exp Eye Res. 2005;80:249–258.
16. Funatsu H, Yamashita H, Noma H, Mimura T, Yamashita T, Hori S. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol. 2002;133:70–77.
17. Campochiaro PA, Nguyen QD, Hafiz G, et al. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology. 2013;120:583–587.
18. Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a doublemasked, placebo-controlled, randomized clinical trial. Ophthalmology. 2006;113:1533–1538.
19. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109:920–927.
20. Bressler NM, Edwards AR, Beck RW, et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Arch Ophthalmol. 2009;127:1566–1571.
21. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008;115:1447–1449.
22. Campochiaro PA, Hafiz G, Shah SM, et al; FAMOUS Study Group. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology. 2010;117:1393–1399.
23. ILUVIEN® [summary of product characteristics]. Last updated on eMC 18-Feb-2014. Available from: https://www.medicines.org.uk/emc/medicine/27636. Accessed July 24, 2014.
24. Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119:2125–2132.
25. Cunha-Vaz J, Ashton P, Iezzi R, et al. Sustained delivery fluocinolone acetonide vitreous implants. Ophthalmology. 2014;121:1892–1903.
26. Neubauer AS, Ulbig MW. Laser treatment in diabetic retinopathy. Ophthalmologica. 2007;221:95–102.
27. Nguyen QD, Shah SM, Khwaja AA, et al. Two year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology. 2010;117:2146–2151.
28. Bressler NM, Varma R, Suñer IJ, et al. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE. Ophthalmology. 2014;121(12):2461–2472.
29. Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120:2013–2022.
30. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789–801. Supplemental material (Table 6). Available from: http://www.aaojournal.org/cms/attachment/ 2005446053/2023774732/mmc1.pdf. Accessed August 22, 2014.